The role of choroid plexus in IVIG-induced beta-amyloid clearance

Neuroscience

Volumn 270, Issue , 2014, Pages 168-176

  Gu, H ^a   Zhong, Z ^a,b   Jiang, W ^c   Du, E ^a   Dodel, R ^d   Liu, J ^e   Farlow, M R ^a   Zheng, W ^c   Du, Y ^a,c  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^c PURDUE UNIVERSITY   (United States)

^d PHILIPPS UNIVERSITY MARBURG   (Germany)

^e PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

A clearance; Choroid plexus; IVIG; LRP1

Indexed keywords

AMYLOID PRECURSOR PROTEIN; IMMUNOGLOBULIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; SMALL INTERFERING RNA; AMYLOID BETA PROTEIN; APP PROTEIN, HUMAN; IMMUNOLOGIC FACTOR; LOW DENSITY LIPOPROTEIN RECEPTOR; LRP1 PROTEIN, MOUSE; TUMOR SUPPRESSOR PROTEIN;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CEREBROSPINAL FLUID BARRIER; BRAIN LEVEL; BRAIN REGION; CHOROID PLEXUS; CONTROLLED STUDY; DRUG MECHANISM; FUNCTIONAL ANATOMY; IN VITRO STUDY; MOUSE; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TRANSPORT; RAT; ANIMAL; BLOOD; BRAIN CORTEX; C57BL MOUSE; CELL LINE; CEREBROSPINAL FLUID; CULTURE TECHNIQUE; DRUG EFFECTS; EPITHELIUM CELL; GENE SILENCING; GENETICS; HIPPOCAMPUS; HUMAN; METABOLISM; TRANSGENIC MOUSE; WESTERN BLOTTING;

AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BLOTTING, WESTERN; CELL CULTURE TECHNIQUES; CELL LINE; CEREBRAL CORTEX; CHOROID PLEXUS; EPITHELIAL CELLS; GENE KNOCKDOWN TECHNIQUES; HIPPOCAMPUS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; MICE, INBRED C57BL; MICE, TRANSGENIC; RATS; RECEPTORS, LDL; RNA, SMALL INTERFERING; TUMOR SUPPRESSOR PROTEINS;

EID: 84899860531     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2014.04.011     Document Type: Article

References (53)

1. Bacher M., Depboylu C., Du Y., Noelker C., Oertel W.H., Behr T., Henriksen G., Behe M., Dodel R. Peripheral and central biodistribution of (111)In-labeled anti-beta-amyloid autoantibodies in a transgenic mouse model of Alzheimer's disease. Neurosci Lett 2009, 449:240-245.
2. Bales K.R., Verina T., Cummins D.J., Du Y., Dodel R.C., Saura J., Fishman C.E., DeLong C.A., Piccardo P., Petegnief V., Ghetti B., Paul S.M. Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 1999, 96:15233-15238.
3. Bard F., Cannon C., Barbour R., Burke R.L., Games D., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Lieberburg I., Motter R., Nguyen M., Soriano F., Vasquez N., Weiss K., Welch B., Seubert P., Schenk D., Yednock T. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000, 6:916-919.
4. Behl M., Zhang Y., Monnot A.D., Jiang W., Zheng W. Increased beta-amyloid levels in the choroid plexus following lead exposure and the involvement of low-density lipoprotein receptor protein-1. Toxicol Appl Pharmacol 2009, 240:245-254.
5. Behl M., Zhang Y., Zheng W. Involvement of insulin-degrading enzyme in the clearance of beta-amyloid at the blood-CSF barrier: consequences of lead exposure. Cerebrospinal Fluid Res 2009, 6:11.
6. Brown P.D., Davies S.L., Speake T., Millar I.D. Molecular mechanisms of cerebrospinal fluid production. Neuroscience 2004, 129:957-970.
7. Crossgrove J.S., Li G.J., Zheng W. The choroid plexus removes beta-amyloid from brain cerebrospinal fluid. Exp Biol Med (Maywood) 2005, 230:771-776.
8. Crossgrove J.S., Smith E.L., Zheng W. Macromolecules involved in production and metabolism of beta-amyloid at the brain barriers. Brain Res 2007, 1138:187-195.
9. Deane R., Wu Z., Sagare A., Davis J., Du Yan S., Hamm K., Xu F., Parisi M., LaRue B., Hu H.W., Spijkers P., Guo H., Song X., Lenting P.J., Van Nostrand W.E., Zlokovic B.V. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 2004, 43:333-344.
10. DeMattos R.B., Bales K.R., Cummins D.J., Paul S.M., Holtzman D.M. Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 2002, 295:2264-2267.
11. Dodel R., Hampel H., Depboylu C., Lin S., Gao F., Schock S., Jackel S., Wei X., Buerger K., Hoft C., Hemmer B., Moller H.J., Farlow M., Oertel W.H., Sommer N., Du Y. Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease. Ann Neurol 2002, 52:253-256.
12. Dodel R., Neff F., Noelker C., Pul R., Du Y., Bacher M., Oertel W. Intravenous immunoglobulins as a treatment for Alzheimer's disease: rationale and current evidence. Drugs 2010, 70:513-528.
13. Donahue J.E., Flaherty S.L., Johanson C.E., Duncan J.A., Silverberg G.D., Miller M.C., Tavares R., Yang W., Wu Q., Sabo E., Hovanesian V., Stopa E.G. RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease. Acta Neuropathol 2006, 112:405-415.
14. Du Y., Dodel R., Hampel H., Buerger K., Lin S., Eastwood B., Bales K., Gao F., Moeller H.J., Oertel W., Farlow M., Paul S. Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology 2001, 57:801-805.
15. Du Y., Wei X., Dodel R., Sommer N., Hampel H., Gao F., Ma Z., Zhao L., Oertel W.H., Farlow M. Human anti-beta-amyloid antibodies block beta-amyloid fibril formation and prevent beta-amyloid-induced neurotoxicity. Brain 2003, 126:1935-1939.
16. Fabian T. Prof. Imre Vamos, DDS. 1928-1980. Fogorv Sz 1980, 73:193-194.
17. Fanning A.S., Mitic L.L., Anderson J.M. Transmembrane proteins in the tight junction barrier. J Am Soc Nephrol 1999, 10:1337-1345.
18. Fujiyoshi M., Tachikawa M., Ohtsuki S., Ito S., Uchida Y., Akanuma S., Kamiie J., Hashimoto T., Hosoya K., Iwatsubo T., Terasaki T. Amyloid-beta peptide(1-40) elimination from cerebrospinal fluid involves low-density lipoprotein receptor-related protein 1 at the blood-cerebrospinal fluid barrier. J Neurochem 2011, 118:407-415.
19. Ghosh A.K., Hong L., Tang J. Beta-secretase as a therapeutic target for inhibitor drugs. Curr Med Chem 2002, 9:1135-1144.
20. Goto J.J., Tanzi R.E. The role of the low-density lipoprotein receptor-related protein (LRP1) in Alzheimer's A beta generation: development of a cell-based model system. J Mol Neurosci 2002, 19:37-41.
21. Gu H., Wei X., Monnot A.D., Fontanilla C.V., Behl M., Farlow M.R., Zheng W., Du Y. Lead exposure increases levels of beta-amyloid in the brain and CSF and inhibits LRP1 expression in APP transgenic mice. Neurosci Lett 2011, 490:16-20.
22. Gu H., Robison G., Hong L., Barrea R., Wei X., Farlow M.R., Pushkar Y.N., Du Y., Zheng W. Increased beta-amyloid deposition in Tg-SWDI transgenic mouse brain following in vivo lead exposure. Toxicol Lett 2012, 213:211-219.
23. Hammad S.M., Ranganathan S., Loukinova E., Twal W.O., Argraves W.S. Interaction of apolipoprotein J-amyloid beta-peptide complex with low density lipoprotein receptor-related protein-2/megalin. A mechanism to prevent pathological accumulation of amyloid beta-peptide. J Biol Chem 1997, 272:18644-18649.
24. Hartz A.M., Miller D.S., Bauer B. Restoring blood-brain barrier P-glycoprotein reduces brain amyloid-beta in a mouse model of Alzheimer's disease. Mol Pharmacol 2010, 77:715-723.
25. Hayashi S., Yamamoto M., Tachibana K., Ueno Y., Bu G., Fukushima T. Mechanism of photofrin-enhanced ultrasound-induced human glioma cell death. Anticancer Res 2009, 29:897-905.
26. Herz J., Strickland D.K. LRP: a multifunctional scavenger and signaling receptor. J Clin Invest 2001, 108:779-784.
27. Hyslop P.A., Bender M.H. Methods for sample preparation for direct immunoassay measurement of analytes in tissue homogenates: ELISA assay of amyloid beta-peptides. Curr Protoc Neurosci 2002, Chapter 7:Unit 7 20.
28. Janus C., Pearson J., McLaurin J., Mathews P.M., Jiang Y., Schmidt S.D., Chishti M.A., Horne P., Heslin D., French J., Mount H.T., Nixon R.A., Mercken M., Bergeron C., Fraser P.E., St George-Hyslop P., Westaway D. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000, 408:979-982.
29. Kalaria R.N., Premkumar D.R., Pax A.B., Cohen D.L., Lieberburg I. Production and increased detection of amyloid beta protein and amyloidogenic fragments in brain microvessels, meningeal vessels and choroid plexus in Alzheimer's disease. Brain Res Mol Brain Res 1996, 35:58-68.
30. Kanekiyo T., Bu G. Receptor-associated protein interacts with amyloid-beta peptide and promotes its cellular uptake. J Biol Chem 2009, 284:33352-33359.
31. Knauer M.F., Orlando R.A., Glabe C.G. Cell surface APP751 forms complexes with protease nexin 2 ligands and is internalized via the low density lipoprotein receptor-related protein (LRP). Brain Res 1996, 740:6-14.
32. Kounnas M.Z., Moir R.D., Rebeck G.W., Bush A.I., Argraves W.S., Tanzi R.E., Hyman B.T., Strickland D.K. LDL receptor-related protein, a multifunctional ApoE receptor, binds secreted beta-amyloid precursor protein and mediates its degradation. Cell 1995, 82:331-340.
33. Maslinska D., Laure-Kamionowska M., Taraszewska A., Deregowski K., Maslinski S. Immunodistribution of amyloid beta protein (Abeta) and advanced glycation end-product receptors (RAGE) in choroid plexus and ependyma of resuscitated patients. Folia Neuropathol 2011, 49:295-300.
34. Moir R.D., Tanzi R.E. LRP-mediated clearance of Abeta is inhibited by KPI-containing isoforms of APP. Curr Alzheimer Res 2005, 2:269-273.
35. Monro O.R., Mackic J.B., Yamada S., Segal M.B., Ghiso J., Maurer C., Calero M., Frangione B., Zlokovic B.V. Substitution at codon 22 reduces clearance of Alzheimer's amyloid-beta peptide from the cerebrospinal fluid and prevents its transport from the central nervous system into blood. Neurobiol Aging 2002, 23:405-412.
36. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J., Duff K., Jantzen P., DiCarlo G., Wilcock D., Connor K., Hatcher J., Hope C., Gordon M., Arendash G.W. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000, 408:982-985.
37. Neff F., Wei X., Nolker C., Bacher M., Du Y., Dodel R. Immunotherapy and naturally occurring autoantibodies in neurodegenerative disorders. Autoimmun Rev 2008, 7:501-507.
38. Ogomori K., Kitamoto T., Tateishi J., Sato Y., Suetsugu M., Abe M. Beta-protein amyloid is widely distributed in the central nervous system of patients with Alzheimer's disease. Am J Pathol 1989, 134:243-251.
39. Pascale C.L., Miller M.C., Chiu C., Boylan M., Caralopoulos I.N., Gonzalez L., Johanson C.E., Silverberg G.D. Amyloid-beta transporter expression at the blood-CSF barrier is age-dependent. Fluids Barriers CNS 2011, 8:21.
40. Poduslo J.F., Curran G.L., Kumar A., Frangione B., Soto C. Beta-sheet breaker peptide inhibitor of Alzheimer's amyloidogenesis with increased blood-brain barrier permeability and resistance to proteolytic degradation in plasma. J Neurobiol 1999, 39:371-382.
41. Relkin N.R., Szabo P., Adamiak B., Burgut T., Monthe C., Lent R.W., Younkin S., Younkin L., Schiff R., Weksler M.E. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging 2009, 30:1728-1736.
42. Sasaki A., Iijima M., Yokoo H., Shoji M., Nakazato Y. Human choroid plexus is an uniquely involved area of the brain in amyloidosis: a histochemical, immunohistochemical and ultrastructural study. Brain Res 1997, 755:193-201.
43. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M., Yednock T., Games D., Seubert P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999, 400:173-177.
44. Serot J.M., Bene M.C., Faure G.C. Choroid plexus, aging of the brain, and Alzheimer's disease. Front Biosci 2003, 8:s515-s521.
45. Shabala L., Howells C., West A.K., Chung R.S. Prolonged Abeta treatment leads to impairment in the ability of primary cortical neurons to maintain K+ and Ca2+ homeostasis. Mol Neurodegen 2010, 5:30.
46. Shakibaei M., Frevert U. Dual interaction of the malaria circumsporozoite protein with the low density lipoprotein receptor-related protein (LRP) and heparan sulfate proteoglycans. J Exp Med 1996, 184:1699-1711.
47. Shi L.Z., Zheng W. Establishment of an in vitro brain barrier epithelial transport system for pharmacological and toxicological study. Brain Res 2005, 1057:37-48.
48. Shi L.Z., Li G.J., Wang S., Zheng W. Use of Z310 cells as an in vitro blood-cerebrospinal fluid barrier model: tight junction proteins and transport properties. Toxicol In Vitro 2008, 22:190-199.
49. Shi L.Z., Li G.J., Wang S.Z., Zheng W. Use of Z310 cells as an in vitro blood-cerebro spinal fluid barrier model: Tight junction proteins and transport properties. Toxicol In Vitro 2008, 22:190-199.
50. Smith Q.R. The blood-brain barrier and the regulation of amino acid uptake and availability to brain. Adv Exp Med Biol 1991, 291:55-71.
51. Wang X., Li G.J., Zheng W. Efflux of iron from the cerebrospinal fluid to the blood at the blood-CSF barrier: effect of manganese exposure. Exp Biol Med (Maywood) 2008, 233:1561-1571.
52. Yamada K., Yabuki C., Seubert P., Schenk D., Hori Y., Ohtsuki S., Terasaki T., Hashimoto T., Iwatsubo T. Abeta immunotherapy: intracerebral sequestration of Abeta by an anti-Abeta monoclonal antibody 266 with high affinity to soluble Abeta. J Neurosci 2009, 29:11393-11398.
53. Zheng W., Zhao Q. Establishment and characterization of an immortalized Z310 choroidal epithelial cell line from murine choroid plexus. Brain Res 2002, 958:371-380.